MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2− metastatic breast cancer

類似資料

• Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
  著者:: Rugo, Hope S., 等
  出版事項: (2020)
• Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
  著者:: Johnston, Stephen R. D., 等
  出版事項: (2020)
• Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer
  著者:: Corona, Silvia Paola, 等
  出版事項: (2018)
• Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
  著者:: Johnston, Stephen, 等
  出版事項: (2021)
• Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials
  著者:: Toi, Masakazu, 等
  出版事項: (2021)